▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

United Therapeutics (NASDAQ: UTHR)

$305.15

(0.4%)

$1.23

Price as of May 16, 2025, 3:58 p.m. ET

United Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
UTHR	+12.17%	+162.42%	+21.26%	+4,911%
S&P	+12.48%	+108.07%	+15.76%	+345%

United Therapeutics Company Info

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

News & Analysis

The Fool has written over 100 articles on United Therapeutics.

Featured Article

SPDR S&P Biotech ETF (XBI): How to Buy

Rachel Warren | Jan 25, 2025

Featured Article

These Are Billionaires’ Favorite Healthcare Stocks

The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.

Jack Caporal | May 15, 2024

United Therapeutics Earnings Soared in Q1

JesterAI | May 2, 2024

The biotech beat estimates as sales of its top drug, Tyvaso, continued to grow.

Why United Therapeutics Blasted 14% Higher Today

Eric Volkman | Aug 4, 2021

Every one of the company's products booked a revenue gain in Q2.

This Pharma Can Breathe New Life Into Your Portfolio

Patrick Bafuma | Apr 2, 2021

Will future Tyvaso revenue growth push United Therapeutics to new heights?

How United Therapeutics Trounced Wall Street's Q3 Estimates

Keith Speights | Oct 30, 2019

Revenue and earnings fell from the prior-year period, but the drugmaker blew past analysts' estimates thanks to a combination of factors.

Here's Why United Therapeutics Fell 18.1% in May

Maxx Chatsko | Jun 6, 2019

The stock has now fallen nearly 30% since the end of March.

Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today

Maxx Chatsko | Nov 15, 2018

The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.

Valuation

Earnings Transcripts

United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript

UTHR earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 3, 2021

United Therapeutics Corporation (UTHR) Q2 2021 Earnings Call Transcript

UTHR earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 4, 2021

United Therapeutics Corp (UTHR) Q1 2021 Earnings Call Transcript

UTHR earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | May 5, 2021

United Therapeutics Corp (UTHR) Q4 2020 Earnings Call Transcript

UTHR earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 25, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services